Immunotherapeutic Approaches for Glioblastoma Treatment

Glioblastoma remains a challenging disease to treat, despite well-established standard-of-care treatments, with a median survival consistently of less than 2 years. In this review, we delineate the unique disease-specific challenges for immunotherapies, both brain-related and non-brain-related, whic...

Descripción completa

Detalles Bibliográficos
Autores principales: Yaghi, Nasser K., Gilbert, Mark R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962267/
https://www.ncbi.nlm.nih.gov/pubmed/35203636
http://dx.doi.org/10.3390/biomedicines10020427

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962267/
https://www.ncbi.nlm.nih.gov/pubmed/35203636
http://dx.doi.org/10.3390/biomedicines10020427

Ejemplares similares